Assignee
ROCHE INNOVATION CT COPENHAGEN AS
DK·37 granted patents·55 pending applications·149 citations·filing 2013–2024
Top patents by PatentIndex Score
92 records- 0197US9708614B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Jul 18, 2017·28 cites·36 claims
- 0296US9738894B2Short interfering RNA (siRNA) analoguesROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Aug 22, 2017·55 cites·27 claims
- 0394US10739332B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Aug 11, 2020·6 cites·5 claims
- 0493US10718753B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Jul 21, 2020·5 cites·9 claims
- 0592US9994850B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Jun 12, 2018·4 cites·19 claims
- 0692US9879265B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2014·Granted Jan 30, 2018·17 cites·34 claims
- 0790US10494633B2Oligonucleotides for inducing paternal UBE3A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Dec 3, 2019·8 cites·24 claims
- 0887US12421516B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2023·Granted Sep 23, 2025·0 cites·26 claims
- 0987US10077443B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2013·Granted Sep 18, 2018·10 cites·22 claims
- 1081US11267843B2Stereodefining L-monomersROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Mar 8, 2022·2 cites·4 claims
- 1180US10450564B2MicromirsROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Oct 22, 2019·2 cites·18 claims
- 1278US11739332B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Granted Aug 29, 2023·0 cites·21 claims
- 1378US10443058B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Oct 15, 2019·1 cites·10 claims
- 1478US10385342B2Methods of treatment using antisense oligomers and conjugates targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Aug 20, 2019·1 cites·63 claims
- 1578US10370668B2Manufacture of antisense oligomers and conjugates targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Aug 6, 2019·1 cites·45 claims
- 1676US2020283776A1Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of DiseaseROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 1775US11091764B2Antisense oligomers targeting PCSK9ROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Granted Aug 17, 2021·0 cites·50 claims
- 1874US2021071181A1Pharmaceutical compositionROCHE INNOVATION CT COPENHAGEN AS·Filed 2020·Application pending·0 cites
- 1973US10577388B2Oligonucleotide conjugation processROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Mar 3, 2020·1 cites·31 claims
- 2073US9725723B2Compositions and methods for modulation of FGFR3 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2013·Granted Aug 8, 2017·3 cites·14 claims
- 2173US9566293B2Oral delivery of therapeutically effective LNA oligonucleotidesROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Granted Feb 14, 2017·3 cites·9 claims
- 2273US2021363222A1Soluble TNF Receptors and Their Use in Treatment of DiseaseROCHE INNOVATION CT COPENHAGEN AS·Filed 2020·Application pending·0 cites
- 2373US2019309047A1Soluble TNF Receptors and Their Use in Treatment of DiseaseROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 2472US11261209B2Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotideROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Mar 1, 2022·1 cites·12 claims
- 2572US9790493B2MICROMIRsROCHE INNOVATION CT COPENHAGEN AS·Filed 2014·Granted Oct 17, 2017·1 cites·42 claims
- 2672US2018237777A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 2771US9951333B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Apr 24, 2018·0 cites·30 claims
- 2871US9890383B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Feb 13, 2018·0 cites·30 claims
- 2970US2018237778A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 3068US2021238601A1Oligonucleotide ConjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Application pending·0 cites
- 3168US2017198024A1Soluble TNF Receptors and Their Use in Treatment of DiseaseROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Application pending·0 cites
- 3268US2024368593A1Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkageROCHE INNOVATION CT COPENHAGEN AS·Filed 2024·Application pending·0 cites
- 3366US11155816B2Oligonucleotide conjugatesROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Granted Oct 26, 2021·0 cites·24 claims
- 3466US2016168575A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 3566US2019017052A1Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of DiseaseROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 3665US2019071672A1Pharmaceutical CompositionROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 3765US2016168576A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 3864US2018051290A1Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of DiseaseROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Application pending·0 cites
- 3963US11591594B2LNA-G processROCHE INNOVATION CT COPENHAGEN AS·Filed 2020·Granted Feb 28, 2023·0 cites·21 claims
- 4063US11555050B2Oligonucleotide conjugation processROCHE INNOVATION CT COPENHAGEN AS·Filed 2020·Granted Jan 17, 2023·0 cites·1 claims
- 4162US2018195062A1Pharmaceutical CompositionROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Application pending·0 cites
- 4262US2023002762A1Oligonucleotides comprising a phosphorodithioate internucleoside linkageROCHE INNOVATION CT COPENHAGEN AS·Filed 2022·Application pending·0 cites
- 4362US2017191067A1Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of DiseaseROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Application pending·0 cites
- 4461US2015166634A1Soluble TNF Receptors and Their Use in Treatment of DiseaseROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 4560US9938527B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Apr 10, 2018·0 cites·12 claims
- 4657US2022112493A1Phosphonoacetate gapmer oligonucleotidesROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Application pending·0 cites
- 4756US2016060627A1Pharmaceutical Composition for Inhibition of Disease-inducing microRNAsROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 4855US2017283496A1Oligonucleotides for reduction of pd-l1 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Application pending·0 cites
- 4954US2021269851A1Massively parallel discovery methods for oligonucleotide therapeuticsROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 5054US2022002796A1Quality control of lna oligonucleotide therapeutics using massively parallel sequencingROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
Showing the top 50 of 92 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ROCHE INNOVATION CT COPENHAGEN AS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →